An Open Trial to Assess the Tolerability of AVANZ Salsola Immunotherapy
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
Price : $35 *
At a glance
- Drugs Salsola pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors ALK-Abello
- 05 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 16 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Apr 2014 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT02065856).